<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01656135</url>
  </required_header>
  <id_info>
    <org_study_id>ONErgt11</org_study_id>
    <secondary_id>260687</secondary_id>
    <secondary_id>2011-004301-24</secondary_id>
    <nct_id>NCT01656135</nct_id>
  </id_info>
  <brief_title>Reference Group Trial for The ONE Study</brief_title>
  <official_title>Reference Group Trial for The ONE Study: A Unified Approach to Evaluating Cellular Immunotherapy in Solid Organ Transplantation</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>University of Regensburg</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>European Commission</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>University of Regensburg</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      To investigate the progression of the immunological response in living-donor kidney&#xD;
      transplant recipients treated with a standard immunosuppressive regimen. Clinical,&#xD;
      immunological, and health-economic data collected during this Reference Group Trial will be&#xD;
      used to corroborate historical renal transplantation statistics and generate reference ranges&#xD;
      for future clinical studies that will test immunoregulatory cell therapy as an adjunct&#xD;
      immunosuppressive treatment in renal transplantation.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>December 2012</start_date>
  <completion_date type="Actual">December 2015</completion_date>
  <primary_completion_date type="Actual">December 2015</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Basic Science</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>biopsy-confirmed acute rejection incidence</measure>
    <time_frame>60 weeks</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>time to first acute rejection episode</measure>
    <time_frame>within 60 weeks</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>severity of acute rejection episodes</measure>
    <time_frame>within 60 weeks</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>total immunosuppressive burden</measure>
    <time_frame>60 weeks</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>incidence of chronic graft dysfunction</measure>
    <time_frame>60 weeks</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>incidence of graft loss through rejection</measure>
    <time_frame>60 weeks</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>incidence of adverse drug reactions</measure>
    <time_frame>60 weeks</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>incidence of major infections</measure>
    <time_frame>60 weeks</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>incidence of neoplasia</measure>
    <time_frame>60 weeks</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>incidence of patients treated for subclinical acute rejection</measure>
    <time_frame>60 weeks</time_frame>
  </secondary_outcome>
  <other_outcome>
    <measure>Immune Monitoring (IM) assessment</measure>
    <time_frame>60 weeks</time_frame>
  </other_outcome>
  <other_outcome>
    <measure>Health Economics (HEC) assessment</measure>
    <time_frame>60 weeks</time_frame>
  </other_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Actual">70</enrollment>
  <condition>End-stage Renal Failure</condition>
  <condition>Kidney Graft Rejection</condition>
  <arm_group>
    <arm_group_label>Reference Group</arm_group_label>
    <arm_group_type>Other</arm_group_type>
    <description>Basiliximab (Simulect®):&#xD;
Day 0: 20mg IV ≤2h prior to surgery&#xD;
Day 4: 20mg IV&#xD;
Prednisolone:&#xD;
Day 0: 500mg IV (250mg pre-op, 250mg intra-op)&#xD;
Day 1: 125mg IV&#xD;
Day 2 - 14: 20mg/day oral&#xD;
Week 3 - 4: 15mg/day oral&#xD;
Week 5 - 8: 10mg/day oral&#xD;
Week 9 - 12: 5mg/day oral&#xD;
Week 13 - 14: 2.5mg/day oral&#xD;
Week 15 - Study End: Cessation&#xD;
Steroid tapering should not proceed if graft rejection has occurred or if renal dysfunction is observed.&#xD;
Mycophenolate Mofetil (MMF, or biologic equivalent):&#xD;
Treatment with MMF should commence one day prior to transplantation (on Day -1) and should continue indefinitely, with a dose reduction after two weeks:&#xD;
Day -1 - 14: 2g/day oral&#xD;
Day 15 - Study End 1.5g/day oral (750mg twice daily)&#xD;
Tacrolimus (or biologic equivalent):&#xD;
Day -4 - 14: 3-12ng/ml&#xD;
Week 3 - 12: 3-10ng/ml&#xD;
Week 13 - 36: 3-8ng/ml&#xD;
Week 37 - Study End: 3-6ng/ml</description>
  </arm_group>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Blood drawing for immune monitoring and questionnaires</intervention_name>
    <arm_group_label>Reference Group</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
        Organ Donor:&#xD;
&#xD;
        A prospective donor is eligible for the research if all of the following inclusion criteria&#xD;
        apply:&#xD;
&#xD;
          1. Eligible for live kidney donation&#xD;
&#xD;
          2. Aged at least 18 years&#xD;
&#xD;
          3. An ABO blood type compatible with the organ recipient&#xD;
&#xD;
          4. Willing and able to provide a blood sample for The ONE Study Subprojects&#xD;
&#xD;
          5. Willing to provide personal and medical/biological data for the trial&#xD;
&#xD;
          6. Signed and dated written informed consent.&#xD;
&#xD;
        In signing the donor information sheet/informed consent form (DIS/ICF), organ donors agree&#xD;
        to provide a blood sample for the IM Subproject, and permit access to their medical records&#xD;
        for the collection of specified demographic and medical/biological data for the trial.&#xD;
&#xD;
        Organ Recipient:&#xD;
&#xD;
          1. Chronic renal insufficiency necessitating kidney transplantation and approved to&#xD;
             receive a primary kidney allograft from a living donor&#xD;
&#xD;
          2. Aged at least 18 years&#xD;
&#xD;
          3. Able to commence the immunosuppressive regimen at the protocol-specified time point&#xD;
&#xD;
          4. Willing and able to participate in The ONE Study subprojects&#xD;
&#xD;
          5. Signed and dated written informed consent.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
        Organ Donor:&#xD;
&#xD;
        If a prospective donor fulfils any of the following criteria, then they are ineligible for&#xD;
        the trial:&#xD;
&#xD;
          1. Genetically identical to the prospective organ recipient at the HLA loci&#xD;
&#xD;
          2. Exposure to any investigational agents at the time of kidney donation, or within 28&#xD;
             days prior to kidney donation&#xD;
&#xD;
          3. Any form of substance abuse, psychiatric disorder, or other condition that, in the&#xD;
             opinion of the Investigator, may invalidate communication with the Investigator and/or&#xD;
             designated study personnel&#xD;
&#xD;
          4. Subjects unable to freely give their informed consent (e.g. individuals under legal&#xD;
             guardianship).&#xD;
&#xD;
        Organ Recipient:&#xD;
&#xD;
          1. Patient has previously received, or is scheduled to receive, any tissue or organ&#xD;
             transplant other than the planned kidney graft&#xD;
&#xD;
          2. Known sensitivity to tacrolimus, mycophenolate, or corticosteroids&#xD;
&#xD;
          3. Genetically identical to the prospective organ donor at the HLA loci&#xD;
&#xD;
          4. PRA grade &gt; 40% within 6 months prior to enrolment&#xD;
&#xD;
          5. Previous treatment with any desensitisation procedure (with or without IVIg)&#xD;
&#xD;
          6. Concomitant malignancy or history of malignancy within 5 years prior to planned study&#xD;
             entry (excluding successfully-treated non-metastatic basal/squamous cell carcinoma of&#xD;
             the skin)&#xD;
&#xD;
          7. Evidence of significant local or systemic infection&#xD;
&#xD;
          8. HIV-positive, EBV-negative or suffering chronic viral hepatitis&#xD;
&#xD;
          9. Significant liver disease, defined as persistently elevated AST and/or ALT levels &gt;2 x&#xD;
             ULN (Upper Limit of Normal range)&#xD;
&#xD;
         10. Malignant or pre-malignant haematological conditions&#xD;
&#xD;
         11. Any uncontrolled medical condition or concurrent disease that could interfere with the&#xD;
             study objectives&#xD;
&#xD;
         12. Any condition which, in the judgement of the Investigator, would place the subject at&#xD;
             undue risk&#xD;
&#xD;
         13. Ongoing treatment with systemic immunosuppressive drugs at study entry&#xD;
&#xD;
         14. Participation in another clinical trial during the study or within 28 days prior to&#xD;
             planned study entry&#xD;
&#xD;
         15. Female patients of child-bearing potential with a positive pregnancy test at enrolment&#xD;
&#xD;
         16. Female patients who are breast-feeding&#xD;
&#xD;
         17. All female patients of child-bearing potential UNLESS:&#xD;
&#xD;
               1. The patient is willing to maintain a highly effective method of birth control for&#xD;
                  the duration of the study&#xD;
&#xD;
               2. The career, lifestyle, or sexual orientation of the patient ensures that there is&#xD;
                  no risk of pregnancy for the duration of the study (at the discretion of the&#xD;
                  local Investigator)&#xD;
&#xD;
         18. Psychological, familial, sociological or geographical factors potentially hampering&#xD;
             compliance with the study protocol and follow-up visit schedule&#xD;
&#xD;
         19. Any form of substance abuse, psychiatric disorder, or other condition that, in the&#xD;
             opinion of the Investigator, may invalidate communication with the Investigator and/or&#xD;
             designated study personnel&#xD;
&#xD;
         20. Patients unable to freely give their informed consent (e.g. individuals under legal&#xD;
             guardianship).&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Edward K. Geissler, Ph.D.</last_name>
    <role>Study Director</role>
    <affiliation>University of Regensburg</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>University of California San Francisco</name>
      <address>
        <city>San Francisco</city>
        <state>California</state>
        <zip>94143</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Massachusetts General Hospital</name>
      <address>
        <city>Boston</city>
        <state>Massachusetts</state>
        <zip>02114</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>CHU de Nantes Hotel-Dieu</name>
      <address>
        <city>Nantes</city>
        <zip>44093</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Charite Campus Virchow-Klinikum</name>
      <address>
        <city>Berlin</city>
        <zip>13353</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University Hospital Regensburg</name>
      <address>
        <city>Regensburg</city>
        <zip>93053</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Ospedale San Raffaele</name>
      <address>
        <city>Milan</city>
        <zip>20132</zip>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Guy's Hospital in affiliation with King's College London</name>
      <address>
        <city>London</city>
        <zip>SE1 9RT</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Churchill Hospital in affiliation with the University of Oxford</name>
      <address>
        <city>Oxford</city>
        <zip>OX3 7LE</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>France</country>
    <country>Germany</country>
    <country>Italy</country>
    <country>United Kingdom</country>
    <country>United States</country>
  </location_countries>
  <link>
    <url>http://www.onestudy.org</url>
    <description>The ONE Study</description>
  </link>
  <verification_date>March 2016</verification_date>
  <study_first_submitted>July 31, 2012</study_first_submitted>
  <study_first_submitted_qc>August 1, 2012</study_first_submitted_qc>
  <study_first_posted type="Estimate">August 2, 2012</study_first_posted>
  <last_update_submitted>March 8, 2016</last_update_submitted>
  <last_update_submitted_qc>March 8, 2016</last_update_submitted_qc>
  <last_update_posted type="Estimate">March 9, 2016</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>University of Regensburg</investigator_affiliation>
    <investigator_full_name>Edward Geissler</investigator_full_name>
    <investigator_title>Chief Investigator and EU Project Leader</investigator_title>
  </responsible_party>
  <keyword>gold standard treatment</keyword>
  <keyword>immune monitoring</keyword>
  <keyword>acute rejection</keyword>
  <keyword>graft rejection</keyword>
  <keyword>living-donor</keyword>
  <keyword>renal transplantation</keyword>
  <keyword>kidney transplantation</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Kidney Failure, Chronic</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

